SML1898
艾拉莫德
≥98% (HPLC)
别名:
3-甲酰基氨基-7-甲基磺酰基氨基-6-苯氧基-4H-1-苯并吡喃-4-酮, IGU, N- [3-（甲酰氨基）-4-氧代-6-苯氧基-4H-1-苯并吡喃-7-基]甲磺酰胺, N-（7-（甲基磺酰胺基）-4-氧代-6-苯氧基-4H-铬-3-基）甲酰胺, T-614
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H14N2O6S
化学文摘社编号:
分子量:
374.37
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
艾拉莫德, ≥98% (HPLC)
InChI
1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)
SMILES string
O=S(NC1=CC(OC=C(NC([H])=O)C2=O)=C2C=C1OC3=CC=CC=C3)(C)=O
InChI key
ANMATWQYLIFGOK-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
艾拉莫德（T-614）是一种口服活性抗炎化合物，可抑制NF-κBp65亚基（RelA）的磷酸化和核易位。
艾拉莫德（T-614）是一种抑制NF-κB（NF-KB）p65亚基（RelA）磷酸化和核易位（30 μg/mL抑制10 ng/mL TNF-α;人滑膜细胞）的口服活性抗炎化合物，其不会影响IKBα 的降解。
存储类别
11 - Combustible Solids
wgk
WGK 3
Taro Sakamoto et al.
Anticancer research, 36(7), 3301-3306 (2016-06-30)
Angiogenesis is a known factor for the development of hepatocellular carcinoma (HCC). The aim of this study was to assess the property of iguratimod, that is an anti-inflammatory drug for rheumatoid arthritis, on anti-angiogenesis and anti-carcinogensis for HCC. In vitro
Keiichi Tanaka et al.
Expert review of clinical immunology, 11(5), 565-573 (2015-03-24)
Iguratimod (IGU), a small-molecule compound, was developed as a disease-modifying antirheumatic drug in Japan. The pharmacological studies showed that inhibition of the production of cytokines and immunoglobulins mainly contributes to its improvement effect on animal arthritis models. The first clinical
Joshua Bloom et al.
The Journal of biological chemistry, 291(51), 26502-26514 (2016-10-30)
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that has been implicated in a broad range of inflammatory and oncologic diseases. MIF is unique among cytokines in terms of its release profile and inflammatory role, notably as an endogenous
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持